ARS Pharmaceuticals, Inc. Common Stock (SPRY) Stock
Key stats
- Market cap
- $397.09M
- Price / Earnings ratio
- -1.8x
- EPS (TTM)
- -$2.02
- Volume
- Loading
- 52-week high
- $13.15
- 52-week low
- $2.44
Source: third-party data provider, as of November 13, 2026
Compare with SPRY
Recent news

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SPRY

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY

LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
SPRY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.35
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.33
- MACD histogram
- 0.05
- SMA 50
- $4.15
- Price below SMA 50
- EMA 50
- $4.22
- Price below EMA 50
- SMA 200
- $7.10
- Price below SMA 200
- EMA 200
- $6.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SPRY

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY

LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
SPRY

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit
Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit
SPRY

Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
SPRY

ARS Pharmaceuticals Q2 Earnings Call Highlights
ARS Pharmaceuticals Q2 Earnings Call Highlights
SPRY

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
SPRY

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
SPRY

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY
News tone: automated (AI) classification of the article's content, not a price prediction.
About ARS Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Donn Casale | CEO, President & Director | 1973 |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer | — |
| Mr. Brian T. Dorsey M.S. | Chief Operating Officer | 1969 |
| Mr. Justin Chakma | Chief Business Officer | 1990 |
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer | — |
| Mr. Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary | 1967 |
| Mr. Daniel Relovsky | Senior Vice President of Marketing | — |
| Ms. Lynda Harris | Vice President of Human Resources | — |
| Mr. Eric Karas | Chief Commercial Officer | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.35
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.33
- MACD histogram
- 0.05
- SMA 50
- $4.15
- Price below SMA 50
- EMA 50
- $4.22
- Price below EMA 50
- SMA 200
- $7.10
- Price below SMA 200
- EMA 200
- $6.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $17.00
- Average
- $18.50
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | +2.6 | +31.6 | ||||||||||
| 2023 | -18.5 | +28.3 | -28.2 | +2.7 | +6.9 | -2.5 | +9.2 | -1.4 | -46.8 | -7.0 | +35.7 | +10.7 |
| 2024 | +11.3 | +30.8 | +17.3 | -8.1 | -4.8 | -5.9 | +24.5 | +23.7 | +21.4 | +1.8 | -4.9 | -20.8 |
| 2025 | +21.6 | -14.9 | +23.6 | +11.5 | +1.9 | +20.7 | +9.9 | -32.4 | -9.6 | -11.2 | +10.7 | +23.9 |
| 2026 | -13.1 | -9.9 | -12.4 | +1.8 | +6.0 | -15.1 | -35.4 | +9.9 | -25.3 | -18.0 | +29.5 |



